125 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) each “employee benefit plan” (within the meaning of Section 3(3) of the Employee … .
(vv) Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee, affiliate or other person
S-8
kyv99 965
31 Jan 24
Registration of securities for employees
4:19pm
8-K
EX-10.1
1zih vtzsk44mwlp
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
8-K
vfrgwxa
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
S-8
y46iqxbbh8oh4t
17 Jan 24
Registration of securities for employees
4:06pm
S-3ASR
0jzluucd
2 Jan 24
Automatic shelf registration
4:06pm
S-3ASR
EX-4.3
0ws4h5aqwu845lm0yx0v
2 Jan 24
Automatic shelf registration
4:06pm
144
0i6u aj8387k2h
14 Dec 23
Notice of proposed sale of securities
5:09pm
8-K
EX-1.1
a00eq8bj
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.2
zzntz
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
qara4l6xr348ud5whkpp
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
r9u64mhxhl fi
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
ph7j60zr69rscfatf4a
27 Sep 23
Prospectus supplement for primary offering
5:26pm